Departments of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, 71103, USA.
School of Medicine, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA.
Adv Ther. 2024 Nov;41(11):4299-4311. doi: 10.1007/s12325-024-02980-0. Epub 2024 Sep 13.
This analysis is a systematic literature review assessing efficacy and adverse effects of three alpha-2 agonists for the symptomatic management of autism spectrum disorder (ASD).
The present investigation involved an extensive systematic search for eligible studies in PubMed, Embase, Cochrane Library, and Google Scholar. Nine studies, collectively incorporating 226 patients, were assessed.
The results demonstrated promising indications for use of alpha-2 agonists in the symptomatic management of autism spectrum disorders, including improvement of hyperactivity, impulsivity, attention deficit symptoms, irritability, and stereotypies in many of the participants studied.
The present investigation encourages physicians to consider treatment outcomes of clonidine, guanfacine, and lofexidine to determine the most effective management of ASD-related symptoms and to minimize adverse effects. However, our review cannot provide definitive treatment protocols related to various study limitations.
本分析是一项系统文献综述，评估了三种 α-2 激动剂在自闭症谱系障碍（ASD）症状管理中的疗效和不良反应。
本研究在 PubMed、Embase、Cochrane 图书馆和 Google Scholar 中进行了广泛的系统检索，以寻找符合条件的研究。评估了 9 项研究，共纳入 226 名患者。
研究结果表明，α-2 激动剂在自闭症谱系障碍的症状管理中具有应用前景，包括改善多动、冲动、注意力缺陷症状、易怒和刻板行为等，在许多研究参与者中都有改善。
本研究鼓励医生考虑氯硝西泮、胍法辛和可乐定的治疗效果，以确定 ASD 相关症状的最有效管理方法，并最小化不良反应。然而，由于各种研究局限性，我们的综述无法提供明确的治疗方案。
